Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

S.      Tangri; C.      LiCalsi; J.      Sidney; A.      Sette

doi:10.2174/0929867023368647

Abstract

One challenge associated with the clinical use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions. The molecular basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the

Keywords: epitope, immunostealth, antibody, htl

Rights & Permissions Print Cite

Current Medicinal Chemistry

Title: Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

Volume: 9 Issue: 24

Author(s): S. Tangri, C. LiCalsi, J. Sidney and A. Sette

Affiliation:

Keywords: epitope, immunostealth, antibody, htl

Abstract: One challenge associated with the clinical use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions. The molecular basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Tangri S., LiCalsi C., Sidney J. and Sette A., Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity, Current Medicinal Chemistry 2002; 9 (24) . https://dx.doi.org/10.2174/0929867023368647

DOI https://dx.doi.org/10.2174/0929867023368647	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X

About this journal

Call for Papers in Thematic Issues

Submission closes on : 31 December, 2025

Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.

The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more

Guest Editor(s): Dr. Geir Bjørklund

Submission closes on : 31 December, 2025

Approaches to the Treatment of Chronic Inflammation

Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more

Guest Editor(s): Dr. Vladimir Rogovskii

Submission closes on : 31 December, 2025

Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications

The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more

Guest Editor(s): Dr. Igor A. Sobenin

Submission closes on : 31 December, 2025

Chalcogen-modified nucleic acid analogues

Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

Guest Editor(s): Dr. Katarzyna Kulik